Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286035 | 0.81 | NPC1 (0.31) | — | |
| SCHEMBL10286367 | 0.80 | UGT2B17 (0.38) | UGT2B17ACHE | |
| SCHEMBL10286383 | 0.79 | UGT2B17 (0.33) | UGT2B17ACHE | |
| SCHEMBL10286351 | 0.76 | UGT2B17 (0.34) | UGT2B17ACHE | |
| SCHEMBL10286182 | 0.74 | UGT2B17 (0.35) | UGT2B17ACHE | |
| SCHEMBL10287385 | 0.74 | UGT2B17 (0.42) | UGT2B17ACHE | |
| SCHEMBL10286291 | 0.71 | MAPT (0.34) | UGT2B17ACHE | |
| SCHEMBL6475145 | 0.70 | DDB1 (0.41) | — | |
| SCHEMBL23782941 | 0.70 | UGT2B17 (0.33) | UGT2B17ACHE | |
| SCHEMBL17128342 | 0.70 | UGT2B17 (0.33) | UGT2B17ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| EP-0187977-B1 | TETRAHYDROQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND ANTI-PEPTIC ULCER COMPOSITIONS CONTAING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4880815-A | GASTRIC JUICE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4738970-A | Benzimidazolyl-thio-tetrahydroquinolines and anti-peptic ulcer compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0187977-A1 | Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | UGT2B17 1446/4885ACHE 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.